Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, Ghent, Belgium.
Chembiochem. 2020 Nov 2;21(21):3036-3043. doi: 10.1002/cbic.202000261. Epub 2020 Jul 10.
Antibody-recruiting molecules (ARMs) are a novel class of immunotherapeutics. They are capable of introducing antibodies onto disease-relevant targets such as cancer cells, bacterial cells or viruses. This can induce antibody-mediated immune responses such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent phagocytosis (ADCP), which can kill the pathogen. In contrast to the classic ARMs, multivalent ARMs could offer the advantage of increasing the efficiency of antibody recruitment and subsequent innate immune killing. Such compounds consist of multiple target-binding termini (TBT) and/or antibody-binding termini (ABT). Those multivalent interactions are able to convert low binding affinities into increased binding avidities. This minireview summarizes the current status of multivalent ARMs and gives insight into possible benefits, hurdles still to be overcome and future perspectives.
抗体募集分子 (ARMs) 是一类新型的免疫治疗药物。它们能够将抗体引入到相关疾病靶点上，如癌细胞、细菌细胞或病毒。这可以诱导抗体介导的免疫反应，如抗体依赖性细胞毒性 (ADCC)、补体依赖性细胞毒性 (CDC) 和抗体依赖性吞噬作用 (ADCP)，从而杀死病原体。与经典的 ARMs 相比，多价 ARMs 可以提高抗体募集和随后的固有免疫杀伤的效率。这些化合物由多个靶结合末端 (TBT) 和/或抗体结合末端 (ABT) 组成。这些多价相互作用能够将低结合亲和力转化为增加的结合亲和力。这篇综述总结了多价 ARMs 的现状，并深入探讨了可能的益处、仍需克服的障碍和未来的展望。
